Document Detail

Diabetes and cancer: Epidemiology and potential mechanisms.
MedLine Citation:
PMID:  25268021     Owner:  NLM     Status:  Publisher    
Type 2 diabetes mellitus is an independent risk factor for cancer such as pancreatic, liver, colorectal and breast cancer. In addition, diabetes decreases the risk of prostate cancer. These associations have been found in numerous epidemiological studies, among them several prospective cohorts. However, such studies do not prove causality of the association and cannot exclude inadequate correction for known confounders (e.g. visceral fat) or the influence of unknown confounders. Thus, it is unclear whether the cancer risk is increased by the causes (e.g. the metabolic syndrome), the metabolic consequences (e.g. hyperglycaemia) or the therapy of diabetes; a question which is of major importance for therapeutic guidelines. Identification of the potential mechanisms by which the diabetes or its therapy accelerates or inhibits the development of cancer will help answering the question by providing biological plausibility. This review will summarize the evidence supporting the association of cancer and type 2 diabetes and discuss its potential causes.
Hans-Georg Joost
Publication Detail:
Type:  REVIEW     Date:  2014-9-29
Journal Detail:
Title:  Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease     Volume:  -     ISSN:  1752-8984     ISO Abbreviation:  Diab Vasc Dis Res     Publication Date:  2014 Sep 
Date Detail:
Created Date:  2014-9-30     Completed Date:  -     Revised Date:  2014-10-1    
Medline Journal Info:
Nlm Unique ID:  101234011     Medline TA:  Diab Vasc Dis Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© The Author(s) 2014.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
Next Document:  Direct effects of recurrent hypoglycaemia on adrenal catecholamine release.